Non-Invasive Cancer Diagnostics Market Size to Reach USD 143.60 Billion by 2034 at a 6.9% CAGR from 2026 to 2034
The non-invasive cancer diagnostics market size was valued at USD 78.77 Billion in 2025 and is expected to reach USD 143.60 billion by 2034, growing at a CAGR of 6.9%.
Key Statistics:
- Market Size (2025): USD 78.77 Billion
- Market Size (2034): USD 143.60 Billion
- CAGR (2026-2034): 6.9%
- Dominating Region: Asia Pacific
Report Highlights:
- Liquid biopsy segment held substantial market share of 20.45% in 2025 due to increasing adoption of blood-based cancer testing technologies.
- Hospitals segment dominated the market by 44.56% revenue share in 2025 due to rising oncology testing procedures and growing investments in cancer diagnostics infrastructure.
- Molecular diagnostics segment is projected to grow at the fastest CAGR of 7.7% during the forecast period due to increasing genomic testing adoption and precision oncology expansion.
- North America dominated the market by 40.79% share in 2025 due to advanced healthcare infrastructure and rising investments in AI-enabled oncology diagnostics.
- Asia Pacific is projected to grow at the fastest CAGR of 7.5% during the forecast period owing to rising healthcare expenditure
What’s Included in Non-Invasive Cancer Diagnostics Report?
The report provides a detailed overview of the non-invasive cancer diagnostics market based on technology, cancer type, and end user. It includes regional analysis, industry dynamics, and competitive landscape.
What are Driving Factors and Emerging Trends of Non-Invasive Cancer Diagnostics Market?
As per analysis, the market is expanding due to rising cancer prevalence and increasing demand for early-stage diagnostics. Key growth factors include:
- Increasing Need for Early Cancer Detection: The healthcare industry is putting more emphasis on early detection and diagnosis of cancers in patients.
- Use of Blood Tests for Cancer Diagnosis: Hospitals and diagnostic centers have increasing the use of liquid biopsy and genomic testing technologies.
- Rising Adoption of AI in Cancer Diagnostics: Organizations are deploying AI in cancer diagnostics through image analysis and pathology solutions.
These factors continue to support long-term market expansion.
Request a free sample copy or read the full market insights: Non-Invasive Cancer Diagnostics Market Report
Which Key Segments are Driving Non-Invasive Cancer Diagnostics Market?
By Technology Analysis
Imaging Diagnostics held the largest market share in 2025 owing to its widespread adoption in cancer screening.
By Cancer Type Analysis
The lung cancer segment dominated the market in 2025 due to rising global lung cancer incidence and increasing adoption of low-dose CT screening technologies.
By End User Analysis
Hospitals segment accounted for the largest market share in 2025 due to increasing oncology testing volumes and growing investments in integrated diagnostics infrastructure.
Which is Dominating Region in Non-Invasive Cancer Diagnostics Market?
Asia Pacific: Asia Pacific is projected to grow at a rapid pace due to increasing healthcare expenditure, expanding diagnostics infrastructure, and rising awareness regarding early-stage cancer screening.
North America: North America led the market due to advanced oncology infrastructure, strong precision medicine adoption, and increasing investments in AI-powered cancer diagnostics technologies.
Where is Non-Invasive Cancer Diagnostics Market Headed?
According to analysis, the market is expected to witness rapid growth owing to increasing precision oncology adoption, rising liquid biopsy commercialization, and growing integration of AI-enabled diagnostics platforms.
What Non-Invasive Cancer Diagnostics Market Report Reveals?
- What is the global market size, growth trend, and CAGR for the non-invasive cancer diagnostics market through 2034?
- What are the key factors driving the growth of the non-invasive cancer diagnostics market?
- What are the leading firms in the non-invasive cancer diagnostics industry, and what is their competitive positioning?
- How is AI improving oncology diagnostics workflows?
- What role does liquid biopsy play in cancer screening expansion?
- What are the key regional trends across North America, Europe, and Asia Pacific?
- Where do new opportunities arise in the non-invasive cancer diagnostics market?
Who are Major Non-Invasive Cancer Diagnostics Market Contributors?
According to our study, a few firms are leading in the global market. The following are some of the major market contributors:
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd.
- Foundation Medicine, Inc.
- Guardant Health
- Illumina
- Koninklijke Philips N.V.
- QIAGEN N.V.
- Siemens Healthineers AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Market Segments Covered
By Technology Outlook (Revenue, USD Billion, 2021–2034)
- Liquid Biopsy
- Molecular Diagnostics
- Imaging Diagnostics
- Biomarker Testing
By Cancer Type Outlook (Revenue, USD Billion, 2021–2034)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
By End User Outlook (Revenue, USD Billion, 2021–2034)
- Hospitals
- Diagnostic Laboratories
- Cancer Research Centers
- Specialty Clinics
- Others
By Regional Outlook (Revenue, USD Billion, 2021-2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherland
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of Middle East & Africa
